Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664097 | 0.96 | TSHR (0.55) | TSHRL3MBTL1ZDHHC20RECQLSMN1; SMN2 | |
| SCHEMBL23853623 | 0.94 | TSHR (0.56) | TSHRL3MBTL1ZDHHC20EPHX2 | |
| SCHEMBL26923326 | 0.93 | TSHR (0.55) | TSHRL3MBTL1ZDHHC20SMN1; SMN2EPHX2 | |
| SCHEMBL4173227 | 0.88 | TSHR (0.52) | TSHRL3MBTL1ZDHHC20SMN1; SMN2ALDH1A1 | |
| SCHEMBL998277 | 0.85 | TSHR (0.48) | TSHRL3MBTL1SMN1; SMN2ALDH1A1TAAR1 | |
| SCHEMBL20840269 | 0.85 | TSHR (0.48) | TSHRL3MBTL1SMN1; SMN2ALDH1A1TAAR1 | |
| SCHEMBL13736171 | 0.85 | TSHR (0.48) | TSHRL3MBTL1SMN1; SMN2ALDH1A1TAAR1 | |
| SCHEMBL13738486 | 0.85 | TSHR (0.48) | TSHRL3MBTL1SMN1; SMN2ALDH1A1TAAR1 | |
| SCHEMBL22609950 | 0.84 | TSHR (0.42) | TSHRL3MBTL1ZDHHC20 | |
| SCHEMBL26923742 | 0.83 | TSHR (0.39) | TSHRL3MBTL1RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885L3MBTL1 1394/4885ZDHHC20 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.